Lamorde, MohammedByakika-Kibwika, PaulineOkaba-Kayom, VioletFlaherty, John P.Boffito, MartaNamakula, RhodaRyan, MairinNakabiito, ClemensiaBack, David J.Khoo, SayeMerry, ConceptaScarsi, Kimberly K.2022-01-132022-01-132010Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Flaherty, J. P., Boffito, M., Namakula, R., ... & Scarsi, K. K. (2010). Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1–Seropositive Ugandan Women. Journal of acquired immune deficiency syndromes (1999), 55(3), 345.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594885/https://nru.uncst.go.ug/xmlui/handle/123456789/1269Conflicting data exist regarding the effect of pregnancy on steady-state nevirapine pharmacokinetics (PK), although steady-state nevirapine concentrations during pregnancy have never been characterized in sub-Saharan Africa. Methods: This was a longitudinal intensive PK study in Ugandan pregnant women receiving nevirapine-based antiretroviral therapy. Participants underwent intensive 12-hour PK sampling during the second trimester (T2; n = 4), third trimester (T3; n = 15) and 6 weeks postpartum (PP; n = 15). HIV-1 RNAwas performed within 2weeks of each visit. Nevirapine C12 above 3000 ng/mLwas classified as optimal based on the suggested value for therapeutic drug monitoring.enAntiretroviral agentsHIVPregnancyPharmacokineticsSub-Saharan AfricaArticle